Voiant, LLC

Voiant is a clinical trial imaging Contract Research Organization (CRO) specializing in AI-powered imaging solutions for biopharmaceutical companies. With over 30 years of clinical expertise, Voiant delivers high-quality imaging endpoint data and endpoint adjudication services supporting therapies across oncology, ophthalmology, and respiratory indications from Phase I-IV global trials. The company operates a proprietary, purpose-built AI platform that accelerates imaging processing and analysis while maintaining scientific accuracy through expert human oversight. Voiant's services include independent reading center operations, blinded imaging review (BICR), and specialized imaging biomarker analysis. The company has expanded AI capabilities through acquisition of Voxeleron and maintains a global network of subspecialty-trained clinical readers, regulatory expertise, and over 2,700 registered clinical trial sites. Voiant has contributed to multiple FDA-approved therapies and serves as a trusted partner for sponsors, CROs, and clinical research organizations seeking reliable, reproducible imaging endpoint data and faster turnaround times.